These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 12218124)

  • 1. Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.
    De Pascalis R; Iwahashi M; Tamura M; Padlan EA; Gonzales NR; Santos AD; Giuliano M; Schuck P; Schlom J; Kashmiri SV
    J Immunol; 2002 Sep; 169(6):3076-84. PubMed ID: 12218124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.
    Gonzales NR; Padlan EA; De Pascalis R; Schuck P; Schlom J; Kashmiri SV
    Mol Immunol; 2004 Jul; 41(9):863-72. PubMed ID: 15261458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
    Tamura M; Milenic DE; Iwahashi M; Padlan E; Schlom J; Kashmiri SV
    J Immunol; 2000 Feb; 164(3):1432-41. PubMed ID: 10640759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SDR grafting--a new approach to antibody humanization.
    Kashmiri SV; De Pascalis R; Gonzales NR; Schlom J
    Methods; 2005 May; 36(1):25-34. PubMed ID: 15848072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28.
    Tan P; Mitchell DA; Buss TN; Holmes MA; Anasetti C; Foote J
    J Immunol; 2002 Jul; 169(2):1119-25. PubMed ID: 12097421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity.
    Iwahashi M; Milenic DE; Padlan EA; Bei R; Schlom J; Kashmiri SV
    Mol Immunol; 1999; 36(15-16):1079-91. PubMed ID: 10698310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.
    Kashmiri SV; Iwahashi M; Tamura M; Padlan EA; Milenic DE; Schlom J
    Crit Rev Oncol Hematol; 2001 Apr; 38(1):3-16. PubMed ID: 11255077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.
    Mateo C; Moreno E; Amour K; Lombardero J; Harris W; Pérez R
    Immunotechnology; 1997 Mar; 3(1):71-81. PubMed ID: 9154469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation.
    Kettleborough CA; Saldanha J; Heath VJ; Morrison CJ; Bendig MM
    Protein Eng; 1991 Oct; 4(7):773-83. PubMed ID: 1798701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing.
    Roguska MA; Pedersen JT; Henry AH; Searle SM; Roja CM; Avery B; Hoffee M; Cook S; Lambert JM; Blättler WA; Rees AR; Guild BC
    Protein Eng; 1996 Oct; 9(10):895-904. PubMed ID: 8931129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
    Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
    Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimizing the immunogenicity of antibodies for clinical application.
    Gonzales NR; De Pascalis R; Schlom J; Kashmiri SV
    Tumour Biol; 2005; 26(1):31-43. PubMed ID: 15741769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of human germline genes in a CDR homology-based approach to antibody humanization.
    Hwang WY; Almagro JC; Buss TN; Tan P; Foote J
    Methods; 2005 May; 36(1):35-42. PubMed ID: 15848073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.
    Kashmiri SV; Shu L; Padlan EA; Milenic DE; Schlom J; Hand PH
    Hybridoma; 1995 Oct; 14(5):461-73. PubMed ID: 8575795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies.
    Kolbinger F; Saldanha J; Hardman N; Bendig MM
    Protein Eng; 1993 Nov; 6(8):971-80. PubMed ID: 8309946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenetic analysis of variable regions encoding AB1 and gamma-type AB2 antibodies from the NeuGc-containing ganglioside family.
    Perez A; Lombardero J; Mateo C; Mustelier G; Alfonso M; Vazquez AM; Perez R
    Hybridoma; 2001 Aug; 20(4):211-21. PubMed ID: 11604106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas.
    Mersmann M; Schmidt A; Rippmann JF; Wüest T; Brocks B; Rettig WJ; Garin-Chesa P; Pfizenmaier K; Moosmayer D
    Int J Cancer; 2001 Apr; 92(2):240-8. PubMed ID: 11291052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody humanization by framework shuffling.
    Dall'Acqua WF; Damschroder MM; Zhang J; Woods RM; Widjaja L; Yu J; Wu H
    Methods; 2005 May; 36(1):43-60. PubMed ID: 15848074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework.
    Hanf KJ; Arndt JW; Chen LL; Jarpe M; Boriack-Sjodin PA; Li Y; van Vlijmen HW; Pepinsky RB; Simon KJ; Lugovskoy A
    Methods; 2014 Jan; 65(1):68-76. PubMed ID: 23816785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cloning and molecular characterization of the cDNAs encoding the variable regions of an anti-CD20 monoclonal antibody.
    Shanehbandi D; Majidi J; Kazemi T; Baradaran B; Aghebati-Maleki L
    Hum Antibodies; 2017; 26(1):1-6. PubMed ID: 28269762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.